TY - JOUR AU - Kim, Seung Tae AU - Jang, Kee-Taek AU - Lee, Su Jin AU - Jang, Hye-Lim AU - Lee, Jeeyun AU - Park, Se Hoon AU - Park, Young Suk AU - Lim, Ho Yeong AU - Kang, Won Ki AU - Park, Joon Oh PY - 2015 DA - 2015/07/21 TI - Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer JO - BMC Cancer SP - 530 VL - 15 IS - 1 AB - The aim of this study was to determine whether early tumor shrinkage (ETS) at 6 weeks after treatment correlates with progression-free survival (PFS) and overall survival (OS) in advanced biliary tract cancer (BTC) patients receiving gemcitabine plus oxaliplatin (GEMOX), with or without erlotinib. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-015-1552-y DO - 10.1186/s12885-015-1552-y ID - Kim2015 ER -